This is a preview of subscription content, log in via an institution to check access.
Notes
Groups newly eligible for treatment include: adults with CD4+ T-cell counts of 350−500 cells/µL; all HIV-infected pregnant women; serodiscordant couples; HIV-infected adults with hepatitis B infection and severe liver disease; and all HIV-infected children aged 2−5 years as well as those aged ≥ 5 years with CD4+ T-cell counts of 350−500 cells/µL.
References
Stover J, et al. The impact and cost of the 2013 WHO recommendations on eligibility for antiretroviral therapy. AIDS 28 (Suppl. 2): S225-30, Mar 2014. Available from: URL: http://doi.org/10.1097/QAD.0000000000000235
Nelson LJ, et al. Adoption of national recommendations related to use of antiretroviral therapy before and shortly following the launch of the 2013 WHO consolidated guidelines. AIDS 28 (Suppl. 2): S217-24, Mar 2014. Available from: URL: http://doi.org/10.1097/QAD.0000000000000239
Rights and permissions
About this article
Cite this article
2013 WHO guidelines on ART eligibility: impact, cost, adoption. PharmacoEcon Outcomes News 704, 2 (2014). https://doi.org/10.1007/s40274-014-1277-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1277-1